Dr. Daniel J. Burdick, MD
Neurology (Neurology Physician)
12039 Ne 128th St, Suite 300
Kirkland, WA 98034
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Johns Hopkins University School of Medicine (2006)
- Years since graduation
- 20
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 246
Licensed in Washington since 2010, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2006Medical school: Johns Hopkins University School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
WA license MD60131025 (first issued 2010; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Evergreenhealth Medical Center Kirkland, WA
- Evergreenhealth Monroe Monroe, WA
Medical groups
- Select Rehabilitation, LLC (2,046 clinicians)
- Select Outpatient Services Inc (805 clinicians)
- King County Public Hospital District No 2 (608 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 246
- Services billed
- 1,141
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 393 | 199 |
| Established patient office or other outpatient visit, 40-54 minutes | 150 | 100 |
| Established patient office or other outpatient visit, 20-29 minutes | 47 | 41 |
| Assessment of and care planning for patient with impaired thought processing, typically 60 minutes | 34 | 34 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator | 25 | 14 |
| Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians a | 25 | 23 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Kirkland, WA | 992 |
| Carbidopa-Levodopa Er (carbidopa/levodopa) Other prescribers in Kirkland, WA | 497 |
| Rytary (carbidopa/levodopa) Other prescribers in Kirkland, WA | 231 |
| Donepezil Hcl Other prescribers in Kirkland, WA | 174 |
| Quetiapine Fumarate Other prescribers in Kirkland, WA | 147 |
| Rasagiline Mesylate | 143 |
| Nuplazid (pimavanserin tartrate) | 136 |
| Ropinirole Hcl Other prescribers in Kirkland, WA | 112 |
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in Kirkland, WA | 103 |
| Midodrine Hcl Other prescribers in Kirkland, WA | 100 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 39 payments worth $1,151 in total to this clinician.
| Boston Scientific Corporation | $257 |
|---|---|
| AbbVie Inc. | $121 |
| Merz Pharmaceuticals, LLC | $120 |
| Tg Therapeutics, Inc. | $91.14 |
| Janssen Biotech, Inc. | $53.69 |
| Novartis Pharmaceuticals Corporation | $44.25 |
| Abbott Laboratories | $43.16 |
| Csl Behring | $42.95 |
| Food and Beverage | $1,151 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 3 companies. The companies reported $89,525 in research payments for these studies, mostly to the institutions running them.
- Open-label Trial in Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04760769 - Open-label Trial in Parkinson s Disease (PD) (TEMPO-4)
AbbVie Inc. - A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
UCB SA · Completed · NCT06055985 - Study to Evaluate SAGE-324 in Participants With Essential Tremors
Sage Therapeutics, LLC - A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
Sage Therapeutics, LLC - Flexible-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-2)
AbbVie Inc. - Flexible-Dose Trial in Early Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04223193
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.